Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Random things, from AGM information

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 09, 2023 10:35am

110 Views

Post# 35385757

RE:RE:RE:Random things, from AGM information

Furthermore, any acquisitor of ONCY will have the ability to out-license pelareorep to any other Big Pharma company with an immune checkpoint inhibitor, CAR-T therapy, bispecific or antibody drug conjugate (ADC) or any of the small molecules PARP, and CDK 4,6 inhibitors, for example.

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – Nov. 6, 2024